Literature DB >> 15692114

A description of Canadian and United States physician reimbursement for thrombolytic therapy administration in acute ischemic stroke.

Dawn Kleindorfer1, Michael D Hill, Daniel Woo, Thomas Tomsick, Arthur Pancioli, Brett Kissela, Andrew M Demchuk, David Losiewicz, Edward Jauch, Alexander Schneider, Andrew Ringer, Daniel Kanter, Joseph P Broderick.   

Abstract

BACKGROUND AND
PURPOSE: Acute ischemic stroke patients are infrequently treated with rtPA, despite its proven effectiveness. Poor physician reimbursement for acute stroke care is one possible explanation for the low frequency of use. We describe the physician reimbursement for thrombolytic therapy for the stroke team physicians serving the Greater Cincinnati/Northern Kentucky region (GCNK), and the Alberta region.
METHODS: GCNK: billing logs were accessed for the study period of 7/01-12/02, and cross-matched to stroke call logs. University of Calgary (UC): treatment records of a single physician were reviewed from 4/02-3/04. A telephone survey of Canadian provinces was conducted regarding billing practices.
RESULTS: GCNK: During the study period, 151 patients received rtPA. For treated pts. the average time spent was 2.6 hours, and average reimbursement received was 472 dollars (of those with insurance). The highest reimbursement was received by billing critical care codes. Reimbursement for critical care was similar to or lower than common office procedures for neurologists. UC: during the study period, 131 patients received rtPA. Average reimbursement for rtPA treated patients was 340 dollars US, not including on-call payments. Survey across Canada revealed many provinces with weekend/after hour premium stipends and on-call stipends.
CONCLUSIONS: Physician reimbursement for the evaluation and treatment of acute stroke, when compared with other diagnoses commonly treated by neurologists, is relatively low in both the U.S. and Canada. Health policy decision-makers in the US and Canada should be made aware of the importance of providing a more balanced plan to provide medical care to stroke patients.

Entities:  

Mesh:

Year:  2005        PMID: 15692114     DOI: 10.1161/01.STR.0000155742.46437.65

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  4 in total

1.  The ABCD and ABCD2 Scores and the Risk of Stroke following a TIA: A Narrative Review.

Authors:  Archit Bhatt; Vishal Jani
Journal:  ISRN Neurol       Date:  2011-07-21

2.  The Massachusetts Emergency Medical Service Stroke Quality Improvement Collaborative, 2009-2012.

Authors:  Denise H Daudelin; Erin R Kulick; Katrina D'Amore; Jennifer S Lutz; Mirian T Barrientos; Kathy Foell
Journal:  Prev Chronic Dis       Date:  2013-09-26       Impact factor: 2.830

Review 3.  Medicolegal considerations with intravenous tissue plasminogen activator in stroke: a systematic review.

Authors:  Archit Bhatt; Adnan Safdar; Dhara Chaudhari; Diane Clark; Amber Pollak; Arshad Majid; Mounzer Kassab
Journal:  Stroke Res Treat       Date:  2013-09-04

4.  Determining intravenous rt-PA eligibility in the Emergency Department.

Authors:  Amy C Mecozzi; Devin L Brown; Lynda D Lisabeth; William G Barsan; Robert Silbergleit; Susan L Hickenbottom; Phillip A Scott; Lewis B Morgenstern
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.532

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.